Description
The PathFinder Tocilizumab Bioassay is an application of the DiscoverX Dimerization Assay platform. The assay is designed to detect the ligand-induced interaction of the interleukin-6 receptor (IL-6R) with the interleukin-6 signal transducer protein (IL-6ST). The cells have been engineered to co-express IL-6ST fused to PK, and IL-6R fused to EA. Binding of an agonist to the IL-6R causes multimerization of the IL-6R and IL-6ST receptors, resulting in activation of downstream signaling events. This brings the two b-gal fragments into close proximity, forcing complementation. Heterodimerization of the two receptor chains results in the formation of a functional b-gal enzyme that hydrolyzes the substrate to generate a chemiluminescent signal. Blocking IL-6 binding with an anti-ligand or anti-receptor antibody can prevent this interaction, resulting in a loss of signal. The bioassay kit contains all reagents needed for the assay, including pre-qualified cryopreserved cells, detection reagents, cell plating reagent, positive control agonist, and assay plates.
Applications
Biosimilar & Biobetter Bioassay
INN Drug Name
Tocilizumab
Molecular Mechanism of Action
Anti-ligand (IL-6) or anti-receptor (IL-6RA) drugs
Qualified With
Actemra®
Assay Measures
Ligand-induced receptor dimerization (IL6RA/IL6ST)
Configuration
10-plate

For Research Use Only | Not For Clinical Use

Online Inquiry
Related Products
Copyright © 2024 Creative Biolabs. All Rights Reserved.